Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Shares Outstanding (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Shares Outstanding data on record, last reported at $158.8 million in Q4 2025.

  • For Q4 2025, Shares Outstanding rose 1.69% year-over-year to $158.8 million; the TTM value through Dec 2025 reached $158.8 million, up 1.69%, while the annual FY2025 figure was $158.8 million, 1.69% up from the prior year.
  • Shares Outstanding reached $158.8 million in Q4 2025 per TGTX's latest filing, roughly flat from $158.8 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $158.8 million in Q4 2025 and bottomed at $41309.0 in Q3 2022.
  • Average Shares Outstanding over 5 years is $113.0 million, with a median of $144.9 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding: plummeted 99.97% in 2023, then soared 374169.66% in 2024.
  • A 5-year view of Shares Outstanding shows it stood at $41309.0 in 2021, then soared by 354366.82% to $146.4 million in 2022, then rose by 3.44% to $151.5 million in 2023, then grew by 3.13% to $156.2 million in 2024, then grew by 1.69% to $158.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $158.8 million in Q4 2025, $158.8 million in Q3 2025, and $158.8 million in Q2 2025.